Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GNFT 
Genfit S.A. (GNFT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GNFT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -24.23% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 187.47M USD | Price to earnings Ratio 8.81 | 1Y Target Price 10.95 |
Price to earnings Ratio 8.81 | 1Y Target Price 10.95 | ||
Volume (30-day avg) 10141 | Beta 1.07 | 52 Weeks Range 3.11 - 6.42 | Updated Date 04/1/2025 |
52 Weeks Range 3.11 - 6.42 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.4 |
Earnings Date
Report Date 2025-04-02 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin 27.68% | Operating Margin (TTM) 51% |
Management Effectiveness
Return on Assets (TTM) 6.51% | Return on Equity (TTM) 25.91% |
Valuation
Trailing PE 8.81 | Forward PE 7.27 | Enterprise Value 181577760 | Price to Sales(TTM) 2.23 |
Enterprise Value 181577760 | Price to Sales(TTM) 2.23 | ||
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA 6.11 | Shares Outstanding 49906500 | Shares Floating 41878105 |
Shares Outstanding 49906500 | Shares Floating 41878105 | ||
Percent Insiders - | Percent Institutions 0.51 |
Analyst Ratings
Rating 4.5 | Target Price 9.97 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Genfit S.A.
Company Overview
History and Background
Genfit S.A. is a biopharmaceutical company focused on discovering and developing innovative therapeutic solutions in areas of high unmet medical needs. Founded in 1999, the company has primarily focused on liver diseases, particularly NASH (nonalcoholic steatohepatitis). Significant milestones include the development of elafibranor, a drug candidate for NASH, and expansion of its research programs.
Core Business Areas
- NASH (Nonalcoholic Steatohepatitis): Development of therapies for NASH, a chronic liver disease.
- PBC (Primary Biliary Cholangitis): Research and development in the field of PBC.
- Diagnostic Solutions: Development of diagnostic tools for liver diseases.
Leadership and Structure
Genfit S.A. is led by a board of directors and an executive management team. The organizational structure comprises research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Elafibranor: A PPAR alpha/delta agonist being investigated for NASH. While it did not meet its primary endpoint in a pivotal Phase 3 trial, research and partnering are still ongoing. Competitors include Madrigal Pharmaceuticals (Resmetirom).
Market Dynamics
Industry Overview
The biopharmaceutical industry is dynamic, with significant investment in research and development of new therapies. The liver disease market, particularly NASH, is experiencing rapid growth due to increasing prevalence and limited treatment options.
Positioning
Genfit aims to be a key player in liver disease therapies, focusing on NASH and related conditions. The company faces competition from larger pharmaceutical companies and smaller biotech firms.
Total Addressable Market (TAM)
The NASH market is projected to reach billions of dollars in the coming years. Genfit's positioning depends on successful development and commercialization of its drug candidates. The NASH market is expected to reach $20-$35 billion by 2030.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Focus on high-unmet-need liver diseases
- Experienced management team
Weaknesses
- Reliance on single pipeline asset (elafibranor)
- Limited commercial infrastructure
- History of clinical trial setbacks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new liver disease indications
- Development of companion diagnostics
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- MRVL
- NVO
Competitive Landscape
Genfit S.A. competes with larger pharmaceutical companies and smaller biotech firms. Its competitive advantage lies in its expertise in liver disease research.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to the progress of elafibranor and other pipeline assets.
Future Projections: Future growth depends on the success of ongoing research programs and potential partnerships.
Recent Initiatives: Recent initiatives include focusing on diagnostic solutions and exploring new therapeutic areas.
Summary
Genfit S.A. is a biopharmaceutical company specializing in liver diseases. Its success heavily relies on the development and commercialization of its pipeline assets, particularly after the setbacks with elafibranor. Partnerships and expansion into new indications could strengthen its market position. The company faces significant competition and regulatory risks. Genfit requires careful monitoring of clinical trial results and strategic partnerships to ensure future growth.
Similar Companies
AKRO
Akero Therapeutics Inc
AKRO
Akero Therapeutics Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MRVL
Marvell Technology Group Ltd
MRVL
Marvell Technology Group Ltd
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry news sources
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genfit S.A.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-03-27 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 169 | Website https://www.genfit.com |
Full time employees 169 | Website https://www.genfit.com | ||
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.